You are here

Article Text

Article menu
Download PDFPDF
Letters
Measuring peak flow enhances adherence to monitoring in asthma
  1. Cassandra A Slader1,
  2. Elena G Belousova2,
  3. Helen K Reddel2
  1. 1Co-operative Research Centre for Asthma, University of Sydney, and Faculty of Pharmacy, University of Sydney, Australia
  2. 2Co-operative Research Centre for Asthma, University of Sydney, and Woolcock Institute of Medical Research, Camperdown, Australia
  1. Correspondence to:
    Dr H K Reddel
    Woolcock Institute of Medical Research, PO Box M77 Camperdown, New South Wales, Australia 2050; hkr{at}med.usyd.edu.au

https://doi.org/10.1136/thx.2006.073395

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Peak expiratory flow (PEF) monitoring is recommended in the management of moderate to severe asthma,1 and PEF outcome variables are used in many clinical trials. However, adherence with PEF monitoring is poor, and this is often attributed to the burden of measurement and recording. This analysis examined whether adherence with symptom monitoring was impaired by asking patients also to record PEF measurements.

    Data were obtained from a randomised double blind study of breathing techniques in adults with poorly controlled asthma. Full details of the clinical trial are reported elsewhere.2 Subjects were non-smokers aged 19–80 years, using reliever as-needed ⩾4 times/week and taking inhaled corticosteroids ⩾200 μg/day. Figure 1 shows the study design, with between-visit intervals of 2 or 6 weeks. Throughout the study, 57 subjects used electronic diary spirometers (AM2, Erich Jaeger GmbH, Hoechberg, Germany) twice daily to answer questions about symptom frequency/intensity and treatment. There were three “PEF periods” during which subjects also measured spirometry twice daily. PEF was displayed after each of three manoeuvres followed by the highest PEF. …

    View Full Text

    Footnotes

    • This study was conducted under the auspices of the Cooperative Research Centre for Asthma, jointly funded by the Australian Federal Government and industry including AstraZeneca, Aventis Pharma, and GlaxoSmithKline. HKR was funded by the Asthma Foundation of New South Wales. CAS was funded by the Australian Government Department of Education, Science and Training via an Australian Postgraduate Award.

    • Competing interests: None.

    • The clinical trial from which these data were obtained was completed in August 2004 and was therefore not required to be registered in a clinical trial registry.

      The study of adherence was initiated by HKR. EGB and CAS conducted data analysis with input from Wei Xuan and HKR. CAS and HKR co-wrote the manuscript. The clinical trial protocol was developed by Christine R Jenkins and HKR and was carried out by CAS, HKR, Karen Symons, Susan Forrest-Blythe, Caroline Reddel, Frank Thien and Ciça Santos, with input from Carol Armour and Sinthia Bosnic-Anticevich.